Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders | GenomeWeb

By Turna Ray

Results from a recent study indicate that healthcare providers may need to use the clinical and pathological features of patients to enrich the population receiving pharmacogenetic testing in order to ensure that personalized cancer treatment strategies are administered in a cost-effective manner.

Such a strategy has a downside, however, since it increases the likelihood of missing patients who might benefit from a personalized oncology therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.